AbbVie Advances Glaucoma Treatment with XEN63 Gel Stent Study

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.

AbbVie has initiated a clinical study titled A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Subjects With Glaucoma. The study aims to assess the safety and effectiveness of the XEN63 gel stent in managing intraocular pressure in glaucoma patients, a leading cause of blindness globally.

The intervention being tested is the XEN63 Glaucoma Treatment System, a gel stent device designed to reduce intraocular pressure. It is being evaluated through two surgical approaches: ab interno (inside the eye) and ab externo (outside the eye).

This Phase 3 interventional study follows a parallel assignment model with single masking, where participants are unaware of the specific intervention they receive. The primary purpose is treatment-focused, aiming to provide a new option for patients who have not responded to other treatments.

The study began on February 11, 2025, with an estimated primary completion date yet to be determined. The latest update was submitted on August 6, 2025, indicating ongoing recruitment efforts.

The successful development of the XEN63 device could significantly impact AbbVie’s market position, potentially boosting its stock performance. It also places AbbVie in a competitive stance within the ophthalmology sector, where advancements in glaucoma treatment are highly sought after.

The study is currently recruiting, with further details available on the ClinicalTrials portal.